Heidelberg Pharma AG (HPHA) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55422	Articles
62513	Press releases

Home
Companies
Heidelberg Pharma AG

BRIEF

published on 04/25/2024 at 07:26, 6 months 26 days ago

Heidelberg Pharma AG Reports on Q1 2024 Financials and Operational Progress

Financial Performance CEO Appointment Heidelberg Pharma AG HDP-101 Clinical Trial ADC Pipeline Development
PRESS RELEASE

published on 04/25/2024 at 07:21, 6 months 26 days ago

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
Heidelberg Pharma AG reports on its interim management statement for the first three months of 2024, including first efficacy data from a clinical trial and successful financing activities

Clinical Trial Heidelberg Pharma AG ADC Pipeline Interim Statement Financing Activities
BRIEF

published on 04/05/2024 at 09:35, 7 months 16 days ago

Heidelberg Pharma to Convene R&D Webinar to Share New Cancer Research Insights

Heidelberg Pharma HDP-101 Multiple Myeloma ADCs R&D Webinar
PRESS RELEASE

published on 04/05/2024 at 09:30, 7 months 16 days ago

Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Heidelberg Pharma AG to host R&D Webinar on 23 April 2024 featuring leading Key Opinion Leaders after presenting novel data at AACR. Event focuses on ADC technologies for cancer treatment

Cancer Treatment Heidelberg Pharma AG R&D Webinar ADC Technologies AACR
BRIEF

published on 03/27/2024 at 09:06, 7 months 25 days ago

Heidelberg Pharma Obtains FDA Orphan Drug Designation for HDP-101 in Multiple Myeloma Treatment

FDA Orphan Drug Designation Heidelberg Pharma HDP-101 Multiple Myeloma
PRESS RELEASE

published on 03/27/2024 at 09:01, 7 months 25 days ago

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Heidelberg Pharma granted orphan drug designation by FDA for its ATAC candidate HDP-101, targeting multiple myeloma. The designation provides significant benefits for the development and potential marketing of the drug

FDA Orphan Drug Designation Heidelberg Pharma Multiple Myeloma ATAC Candidate
BRIEF

published on 03/25/2024 at 07:15, 7 months 27 days ago

Heidelberg Pharma AG Showcases Robust 2023 Performance and Financial Highlights

Cancer Therapy Financial Results 2023 ADC Technology Heidelberg Pharma AG HDP-101 Trial
PRESS RELEASE

published on 03/25/2024 at 07:10, 7 months 27 days ago

Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform

Financial Results Business Performance HDP-101 ADC Technology Heidelberg Pharma AG
BRIEF

published on 03/19/2024 at 09:52, 8 months 2 days ago

Heidelberg Pharma Receives Upfront Payment from HealthCare Royalty Agreement

Heidelberg Pharma HealthCare Royalty Zircaix Antibody Drug Conjugates Biotech Funding
PRESS RELEASE

published on 03/19/2024 at 09:47, 8 months 2 days ago

Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway

Heidelberg Pharma HealthCare Royalty ADC Pipeline Royalty Purchase Agreement Cash Payment

Accesswire

Published on 11/21/2024 at 17:35, 1 hour 10 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 1 hour 15 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 2 hours 15 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 44 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 45 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 18:36, 9 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 47 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 53 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 54 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 2 hours 45 minutes ago

Director/PDMR Shareholding

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 47 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 23 hours 25 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 11 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE